---
layout: default
title: Aluminum Hydroxide Magnesium Carbonate Sodium Bica
parent: 僅模型預測 (L5)
nav_order: 275
evidence_level: L5
indication_count: 0
---

# Aluminum Hydroxide Magnesium Carbonate Sodium Bica
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aluminum Hydroxide / Magnesium Carbonate / Sodium Bicarbonate: Antacid Combination — No Repurposing Candidates Identified

## One-Sentence Summary

Aluminum Hydroxide / Magnesium Carbonate / Sodium Bicarbonate is a classic triple-component antacid combination, widely used in clinical practice to neutralize gastric acid and relieve symptoms of heartburn, acid indigestion, and peptic ulcers.
The TxGNN model **did not generate any repurposing predictions** for this drug combination, likely because the combination product lacks a DrugBank ID mapping required for knowledge graph traversal.
As a result, no clinical trial or literature evidence for a new indication can be presented at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Gastric acid neutralization (heartburn, acid indigestion, peptic ulcer) |
| Predicted New Indication | None identified |
| TxGNN Prediction Score | N/A — no prediction generated |
| Evidence Level | N/A |
| Taiwan Market Status | ✗ Not marketed (0 approved licenses) |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This combination product — aluminum hydroxide, magnesium carbonate, and sodium bicarbonate — functions as a buffering antacid through complementary mechanisms:

- **Aluminum hydroxide** reacts with hydrochloric acid to form aluminum chloride and water, additionally binding dietary phosphate in the gastrointestinal tract.
- **Magnesium carbonate** neutralizes gastric acid and provides a mild laxative effect that counterbalances the constipating tendency of aluminum hydroxide.
- **Sodium bicarbonate** acts as a rapid-onset alkalinizing agent, providing immediate symptom relief.

Despite the DrugBank query returning one result, the drug record could not be resolved to a DrugBank ID (drugbank_id: null). Without a valid DrugBank ID, the TxGNN knowledge graph pipeline cannot traverse drug–disease relationships, and no repurposing predictions are generated. This is a pipeline mapping failure rather than a clinical negative finding — it does not mean this combination has no repurposing potential.

Additionally, this drug combination is not currently marketed in Taiwan (0 TFDA approvals), which further limits regulatory and clinical context.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

*(No predicted indication available; clinical trial retrieval requires a TxGNN-predicted target disease.)*

---

## Literature Evidence

Currently no related literature available.

*(No predicted indication available; literature retrieval requires a TxGNN-predicted target disease.)*

---

## Taiwan Market Information

This drug combination has **no approved licenses** in Taiwan and is classified as **not marketed (未上市)**. No product records were returned from the TFDA query.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data are unavailable for this submission. DrugBank MOA data was also not resolved due to missing DrugBank ID.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model could not process this drug combination because the multi-component product lacks a resolvable DrugBank ID, making knowledge graph traversal impossible. Without a predicted indication, repurposing evaluation cannot proceed. This is a data pipeline issue rather than a clinical verdict.

**To proceed, the following is needed:**

- **Resolve DrugBank mapping**: Query DrugBank for each individual active ingredient separately (DB01122 for aluminum hydroxide, DB09481 for magnesium carbonate, DB01390 for sodium bicarbonate) and run TxGNN predictions on each component independently.
- **Re-run pipeline per component**: Disaggregate the combination and execute KG + DL predictions for each INN individually, then consolidate results.
- **Retrieve MOA data**: Pull mechanism of action descriptions for each component from DrugBank API to enable mechanistic plausibility scoring.
- **Taiwan regulatory review**: Confirm whether any single-ingredient or alternative combination formulations of these antacid components are approved in Taiwan, as this may clarify the regulatory pathway.
- **Safety data remediation**: Download and parse TFDA package insert PDF (DG001) to complete the safety profile before any S1 evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

